Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling

Citation for published version:
Baer, AS, Syed, YA, Kang, SU, Mitteregger, D, Vig, R, Ffrench-Constant, C, Franklin, RJM, Altmann, F, Lubec, G & Kotter, MR 2009, 'Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling' Brain, vol 132, pp. 465-481. DOI: 10.1093/brain/awn334

Digital Object Identifier (DOI):
10.1093/brain/awn334

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Brain

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling

Alexandra S. Baer,1,* Yasir A. Syed,1,* Sung Ung Kang,2,* Dieter Mitteregger,1 Raluca Vig,2 Charles ffrench-Constant,3 Robin J. M. Franklin,4 Friedrich Altmann,5 Gert Lubec2 and Mark R. Kotter1,6

1 Department of Neurosurgery, Medical University Vienna, Vienna, Austria  
2 Department of Pediatrics, Medical University Vienna, Vienna, Austria  
3 MS Society/University of Edinburgh Centre for Translational Research, Centre for Inflammation Research, The Queen’s Medical Research Institute, Edinburgh, UK  
4 Cambridge Centre for Brain Repair and Department of Veterinary Medicine, University of Cambridge, Cambridge, UK  
5 University of Natural Resources and Applied Life Sciences Vienna, Vienna, Austria  
6 Department of Neurosurgery, Georg-August University, Goettingen, Germany

*These authors contributed equally to this work.

Correspondence to: Dr Mark R. Kotter,  
Max Planck Institute for Experimental Medicine and  
Department of Neurosurgery,  
Georg-August University Goettingen,  
37075 Goettingen, Germany  
E-mail: mark.kotter@med.uni-goettingen.de

Abstract

Failure of oligodendrocyte precursor cell (OPC) differentiation contributes significantly to failed myelin sheath regeneration (remyelination) in chronic demyelinating diseases. Although the reasons for this failure are not completely understood, several lines of evidence point to factors present following demyelination that specifically inhibit differentiation of cells capable of generating remyelinating oligodendrocytes. We have previously demonstrated that myelin debris generated by demyelination inhibits remyelination by inhibiting OPC differentiation and that the inhibitory effects are associated with myelin proteins. In the present study, we narrow down the spectrum of potential protein candidates by proteomic analysis of inhibitory protein fractions prepared by CM and HighQ column chromatography followed by BN/SDS–PAGE gel separation using Nano-HPLC-ESI-Q-TOF mass spectrometry. We show that the inhibitory effects on OPC differentiation mediated by myelin are regulated by Fyn-RhoA-ROCK signalling as well as by modulation of protein kinase C (PKC) signalling. We demonstrate that pharmacological or siRNA-mediated inhibition of RhoA-ROCK-II and/or PKC signalling can induce OPC differentiation in the presence of myelin. Our results, which provide a mechanistic link between myelin, a mediator of OPC differentiation inhibition associated with demyelinating pathologies and specific signalling pathways amenable to pharmacological manipulation, are therefore of significant potential value for future strategies aimed at enhancing CNS remyelination.
Introduction

It is well established that cell populations in the adult CNS exist which are able to give rise to cells of all major cell lineages including neurons, oligodendrocytes and astrocytes (Alvarez-Buylla and Lois, 1995; Horn et al., 2000; Nunes et al., 2003). Although the ability of these cells to replace lost neurons is relatively poor their ability to replace oligodendrocytes (and hence remyelinate demyelinated axons) can be very efficient in both experimental models and sometimes in clinical disease (Patrikios et al., 2006; Patani et al., 2007; Blakemore and Franklin, 2008). Remyelination in the CNS is mediated by a multipotent adult stem/precursor cell population traditionally referred to as oligodendrocyte precursor cells (OPCs) (ffrench-Constant and Raff, 1986; Wolswijk and Noble, 1989; Gensert and Goldman, 1997; Carroll et al., 1998; Sim et al., 2002). Although remyelination can be efficient it often fails in clinical disease for reasons that are not fully understood (Franklin, 2002). The chronic demyelination that follows is associated with axonal loss, so providing a possible mechanism for progressive disability in patients suffering from diseases in which chronic demyelination occurs of which the most important is multiple sclerosis. Several lines of evidence both experimental (Woodruff et al., 2004; Foote and Blakemore, 2005) and clinical (Wolswijk, 1998, 2002; Chang et al., 2000; Totoiu and Keirstead, 2005; Kuhlmann et al., 2008) point to the failure of OPC differentiation as a major cause of remyelination failure. Indeed, regulation of OPC differentiation in remyelination represents an attractive model for the more general stem cell medicine challenge of inducing differentiation of repair cells from adult neural stem/precursor cells.

A possible explanation for the failure of OPC differentiation in multiple sclerosis is the presence of inhibitors within demyelinated lesions. A number of potential inhibitors have been proposed including axonal PSA-NCAM in chronically demyelinated lesions (Charles et al., 2002), astrocytic hyaluronan (Back et al., 2005) and notch-jagged (John et al., 2002) signalling, although these are not always supported by functional studies in animals models (Stidworthy et al., 2004). We have previously shown that myelin debris accumulating in lesions as a result of demyelination exerts a powerful inhibitory effect on OPC differentiation unless it is cleared by phagocytes (Kotter et al., 2006). With ageing, the efficiency of myelin debris removal decreases (Ibanez et al., 2004) and this may contribute to the impairment in OPC differentiation that underlies the age-associated decline in remyelination efficiency (Sim et al., 2002; Woodruff et al., 2004).

In this study, we identified potential protein inhibitors by column-chromatography based purification of inhibitory fractions followed by 3D gel electrophoresis and Nano-HPLC-ESI-Q-TOF mass spectrometry. We explored the cell intrinsic mechanisms by which myelin inhibits OPC differentiation in order to identify pathways that can be pharmacologically modulated and hence used as potential remyelination-enhancing therapies. We address the hypothesis that myelin-mediated inhibition of OPC differentiation is mediated by (i) Src-family (Fyn-1)–RhoA-ROCK-II signalling or (ii) protein kinase C (PKC) pathway signalling. By assessing the activation of key molecules of both pathways, we provide evidence of a direct involvement of Src family kinase Fyn and RhoA in mediating the inhibitory effects as well as a modulation of PKC signalling. Our results demonstrate that inhibition of either ROCK-II or PKC is able to induce OPCs differentiation in the presence of myelin thus providing a mechanism which could be of significant therapeutic value.

Materials and methods

Preparation and purification of OPC

Primary cultures of OPCs were isolated from P0 to P2 neonatal Sprague-Dawley rat forebrains following a standard protocol (McCarthy and de Vellis, 1980) that we have adapted for our purposes (Syed et al., 2008). In brief, hemispheres were stripped free of meninges, after a digestion step the cells were plated into cell culture flasks and mixed with 10% FCS at 37°C and 7.5% CO2. To remove the loosely attached microglia, the cells were shaken for 1 h at 260 r.p.m. on an orbital shaker before being shaken at 260 r.p.m. overnight to dislodge the loosely attached oligodendrocyte precursors. OPCs were further purified from contaminating microglia by a differential adhesion step. Subsequently, OPCs were plated onto polylysine (PLL)-coated or substrate coated dishes. To maintain cells at an early precursor stage PDGF-AA (Pepro Tech, Rocky Hill, NJ, USA) and FGF (Pepro Tech) were added (10ng/ml) to SATOs medium. To induce differentiation, cells were incubated in SATOs medium supplemented with 0.5% FCS. The purity of each culture was monitored following OPC purification by immunocytochemistry and only cultures with >94% purity were used. Minor contaminations of microglia, that can be detected by isoclin staining and which amount to 4–5% of the cells, astrocytes (detectable by GFAP) and fibroblasts with distinct morphology and which account for ~1–2% of the cells, were present in the cultures.

Preparation of myelin membrane substrates and myelin protein extracts

Myelin was purified by two rounds of discontinuous density gradient centrifugation and osmotic disintegration (Norton and Poduslo, 1973). Total brains of young Sprague-Dawley rats were homogenized mechanically in ice-cold 0.32 M sucrose using a mechanical blender (Ultra-Turrax; IKA, T18 basic, Germany). Sucrose was dissolved in sterile 2.5 mM Tris/HCl, pH 7.0, to form 0.25, 0.32 and 0.88 M solutions. The homogenized brains were diluted to a final 0.25 M sucrose solution and pelleted in an ultra-centrifuge (55 000 g, 4°C, 15 min). The pellet was re-suspended in 0.88 M sucrose solution and overlaid...
with 0.25 M sucrose. After an ultracentrifugation step (100,000 g, 4°C, 1 h), the interface was collected and washed in 30 ml of distilled H2O (55,000 g, 4°C, 10 min). The pellet was re-suspended in dH2O and incubated for 60 min on ice for osmotic disintegration. After centrifugation (55,000 g, 4°C, 10 min), the flotation step was repeated. The interface was collected and washed twice in dH2O (55,000 g, 4°C, 10 min), and the pellet was stored at −80°C until isolation of myelin protein extracts (MPEs).

To prepare MPE the pellets were resuspended in 1% N-octyl β-D-glucopyranoside, 0.2 M Sodiumphosphate pH 6.8, 0.1 M Na2SO4 and 1 mM EDTA and incubated at 23°C for 1 h, the interface was collected and washed in 30 ml of distilled H2O (55,000 g, 4°C, 10 min), and the pellet was stored at −80°C until isolation of myelin protein extracts (MPEs).

Isolation of liver membrane fractions
Sucrose (0.85 and 1.23 M) in 2.5 mM Tris/HCl was prepared as outlined above. The liver of a young adult Sprague-Dawley rat was extracted and homogenized in 0.85 M sucrose (using an Ultra-Turrax). The homogenate was layered onto a 1.23 M sucrose solution. After centrifugation (100,000 g, 4°C, 1 h) the interface was collected and washed in dH2O (55,000 g, 4°C, 10 min). Finally, the pellet was resuspended in an equal volume of 1× PBS containing 1% octylglucoside and 1 mM EDTA. After incubation at 25°C for 2 h in a shaker the sample was ultracentrifuged at 100,000 g for 30 min and finally, the supernatant was stored at −20°C until further use. The protein concentration was estimated by BCA assay (Pierce, Rockford, IL, USA) (Kotter et al., 2006; Syed et al., 2008).

Chromatography column based separation of inhibitory myelin protein fractions
About 50 ml of the MPE (~1 mg/ml) were filtered through a 0.22 μm Millipore membrane filter. The filtrate was desalted and concentrated using Amicon ultra centrifugal filter devices. The resulting binding and non-binding fractions were again pooled separately. When tested for their inhibitory effects the inhibitory activity was associated with the binding fraction. The pooled binding fractions were further concentrated and the buffer exchanged to a buffer composed of 250 mM 6-aminocaproic acid, 25 mM Bis-Tris, pH 7.0 using Amicon ultra centrifugal filter devices.

One dimensional electrophoresis: BN-PAGE
60 μl of purified inhibitory myelin protein fractions (~2 μg/μl) was added to 10 μl of G250 solution (5% (w/v) Coomassie G250 in 10 mM 6-aminocaproic acid) and loaded onto the gel. BN-PAGE (Wittig et al., 2006) was performed in a PROTEAN II xi Cell (BioRad, Germany) using a 4% stacking and a 5–13% separating gel. The gel buffer contained 250 mM 6-aminocaproic acid, 25 mM Bis-Tris, pH 7.0; the cathode buffer 50 mM Tricine, 15 mM Bis-Tris, 0.05% (w/v) Coomassie G250, pH 7.0; and the anode buffer 50 mM Bis-Tris, pH 7.0. For electrophoresis, the voltage was set to 70 V for 2 h, and was increased to 250 V (10 mA/gel) until the dye front reached the bottom of the gel. BN-PAGE gels were cut into small pieces of ~1–3 cm depending on the intensity of protein bands for the BN/SDS/SDS–PAGE three dimensional electrophoresis (3DE).

Three dimensional electrophoresis: BN/SDS/SDS–PAGE
The experimental procedures and advantages of BN/SDS/SDS–PAGE (3DE) are summarized in Kang et al. (2008). Briefly, 1–3 cm gel pieces from BN-PAGE were soaked for 2 h in a solution of 1% (w/v) SDS and 1% (w/v) 2-mercaptoethanol. Gel pieces were then rinsed twice with SDS–PAGE electrophoresis buffer [25 mM Tris–HCl, 192 mM glycine and 0.1% (w/v) SDS; pH 8.3], then the gel pieces were placed onto the wells. 2DE–SDS–PAGE was performed in PROTEAN II xi Cell using a 4% stacking and a 6–13% separating gel for BN/SDS–PAGE (2DE). Electrophoresis was carried out at 25°C with an initial current of 70 V (during the first hour). The voltage was then set to 100 V for the next 12 h (overnight), and increased to 200 V until the bromophenol blue marker moved 17 cm from the top of separation gel. 2DE gels were cut again into lanes and gel strips from each lane were soaked for 20 min in a solution of 1% (w/v) SDS and 1% (w/v) 2-mercaptoethanol. Gel strips were then rinsed twice with SDS–PAGE electrophoresis buffer (25 mM Tris–HCl, 192 mM glycine and 0.1% (w/v) SDS; pH 8.3), and were placed onto the wells of another gel (3DE). SDS–PAGE was performed in PROTEAN II xi Cell using a 4% stacking and a 7.5–17% separating gel. Electrophoresis was carried out at 25°C with an initial current of 70 V (during the first hour). Then, the voltage was set to 100 V for the next 12 h (overnight), and increased to 200 V until the dye front reached the bottom of the gel. Colloidal Coomassie blue staining was used for visualization.
In-gel digestion of purified myelin fraction with trypsin

The gel pieces of interest were cut into small pieces to increase surface and collected in a 0.6 ml tube. They were initially washed with 50 mM ammonium bicarbonate and then twice with 50% 50 mM ammonium bicarbonate/50% acetonitrile for 30 min with occasional vortexing. The washing solution was discarded at the end of each step. 100 microlitre of 100% acetonitrile was added to each tube to cover the gel piece followed by incubation for at least 5 min. The gel pieces were dried completely in a Speedvac Concentrator 5301 (Eppendorf, Germany). Cysteines were reduced with a 10 mM dithiothreitol solution in 0.1 M ammonium bicarbonate pH 8.6 for 60 min at 56 C. The same volume of a 55 mM solution of iodoacetamide in 0.1 M ammonium bicarbonate buffer pH 8.6 was added and incubated in darkness for 45 min at 25 C to alkylate cysteine residues. The reduction/alkylation solutions were replaced by 50 mM ammonium bicarbonate buffer for 10 min. Gel pieces were washed and dried in acetonitrile followed by Speedvac concentration.

The dried gel pieces were re-swollen with 12.5 ng/µl trypsin (Promega, WI, USA) solution buffered in 25 mM ammonium bicarbonate. They were incubated for 16 h (overnight) at 37 C. Supernatants were transferred to new 0.6 ml tubes, and gel pieces were extracted again with 50 µl of 0.5% formic acid/20% acetonitrile for 15 min in a sonication bath. This step was performed twice. Samples in extraction buffer were pooled in a 0.6 ml tube and evaporated in a Speedvac. The volume was reduced to ~10 µl and 10 µl water was added.

Protein identification with Nano-HPLC-ESI-Q-TOF mass spectrometry

LC-ESI-MS/MS analyses were carried out with the UltiMate 3000 system (Dionex Corporation, Sunnyvale, CA, USA) interfaced to the QSTAR Pulsar mass spectrometer (Applied Biosystems, Foster City, CA, USA). A nanoflow HPLC equipped with a reversed phase PepMap C-18 analytic column (75 µm x 150 mm) was used. Chromatography was performed using a mixture of two solutions, A (0.1% formic acid in water) and B (80% acetonitrile/0.85% formic acid in water), with a flow rate of 300 n l/min. First a linear gradient between 4% and 60% B was run over 45 min, then 90% B was used for 5 min and 0% B for 25 min. Peptide spectra were recorded over the mass range of m/z 350-1300, and MS/MS spectra were recorded under information-dependent data acquisition (IDA) over the mass range of m/z 50-1300. One peptide spectrum was recorded followed by three MS/MS spectra on the QSTAR Pulsar instrument; the accumulation time was 1 s for peptide spectra and 2 s for MS/MS spectra. The collision energy was set automatically according to the mass and charge state of the peptides chosen for fragmentation. Doubly or triply charged peptides were chosen for MS/MS experiments due to their good fragmentation characteristics. MS/MS spectra were interpreted by the MASCOT software (mascot.dll 1.6.2; Matrix Science, London, UK) in Analyst QS 1.1 (Applied Biosystems). Searches were done by using the MASCOT 2.1 (Matrix Science, London, UK) against Swissprot 53.3 and MSGDB 20051115 database for protein identification. Searching parameters were set as follows: enzyme selected as trypsin with a maximum of two missing cleavage sites, species limited to mouse, a mass tolerance of 500 ppm for peptide tolerance, 0.2 Da for MS/MS tolerance, fixed modification of carbamidomethyl (C) and variable modification of methionine oxidation and phosphorylation (Tyr, Thr and Ser).

qPCR for myelin basic protein versus β-2-microglobulin

Total RNA of OPCs grown on PLL control or MPE substrates with various concentrations (0.4 µg MPE, 4 µg MPE and 40 µg MPE) was harvested after the cells were differentiated for 3 days using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instruction.

First strand cDNA synthesis kit for RT–PCR (Roche Applied Science, Vienna, Austria) was used for reverse transcription of 500 ng RNA (each sample) according to the manufacturer’s instructions.

q-PCR was performed using Taqman gene expression assays for myelin basic protein (MBP) (ABI, Foster City, CA, USA, Rn 00566745_M1) and β-2-microglobulin (β2-MG) (ABI, Rn 00560865). Three independent experiments were conducted and all reactions were performed in triplicate on a 7500 Fast Real-Time PCR System. Semi-quantitative mRNA expression levels were calculated with the 7500 Fast System Software (ABI, Foster City, CA).

Pharmacological inhibition of ROCK-II and PKC

To examine whether ROCK-II and PKC signal transduction is implicated in the myelin mediated differentiation block, pharmacological inhibitors were added to the culture medium immediately after cell seeding. The selective PKC-α inhibitor G66976 specific for PKC-α and PKC-β (12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-S-hindolo(2,3-alpyrrollo[3,4-c]carbazole; CAS-number: 136194-77-9) and BIM (Ro 31-8220, Bisindolylmaleimide IX; CAS-number: 125314-64-9) selectively affecting all PKC isoforms were used to block PKC-signalling. To inhibit ROCK-II, an orally available drug currently evaluated for the treatment of vascular disease named Fasudil...
siRNA-based downregulation of RhoA and PKC-α

Ten days after plating mixed glial cultures were transfected with siRNA for PKC-α, RhoA, negative control siRNA and Cyt3™ labelled negative control (Applied Biosystems) using Lipofectamine 2000 (Invitrogen, Paisley, UK) at a concentration of 100 nM according to the manufacturer’s protocol. Twenty-four hours later OPCs were harvested as outlined above. To determine the knock-down efficiency of the targeted genes Western blot analyses were performed for RhoA (Millipore Corporation) or PKC-α (Cell Signalling, Danvers, MA, USA). OPC differentiation was assessed as outlined above 48 h after plating cells onto the experimental substrates; at least three independent experiments were conducted for each condition.

TUNEL assay

Fragmented DNA was detected by incorporation of biotinylated nucleotides at the 3'—OH DNA ends using terminal deoxynucleotidyl transferase recombinant (TdT) enzyme according to the manufacturer's instruction (Promega, Madison, WI, USA). Stained cells were visualized by light microscopy and the percentage of apoptotic nuclei was determined.

Western blot analysis

OPCs differentiated for 24 h and 9 days on PLL were lysed in a buffer containing 10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na3VO4, 0.1% SDS, 0.5% Sodium Deoxycholate, 1% Triton-X100, 10% Glycerol, 1 mM PMSF, 60 μg/ml Aprotinin, 10 μg/ml Leupeptin, 1 μg/ml Pepstatin. After high speed centrifugation, protein concentration was measured using BCA™ protein assay (Pierce) and 15 μg were loaded on SDS–PAGE for separation. Western blot was conducted using a Multiphor II Electrophoresis System (GE Healthcare UK Ltd) at 200 mA for 1 h. After blocking with 5% BSA in TBS-T (0.1% Triton X 100 in TBS) for 1 h at room temperature it was probed overnight at 4°C with the following antibodies: myelin-associated glycoprotein (MAG) (Millipore Corporation), PLP (kindly provided by Lees MB), MBP (DAKO). Following a wash step the membranes were incubated with the appropriate horseradish-peroxidase conjugated secondary antibody (GE Healthcare UK Ltd) for 1 h. The immunoreactive bands were detected by ECL™ chemiluminescence (GE Healthcare UK Ltd) reagent on a film.

Evaluation of Fyn activation

Cells were washed twice with ice cold PBS before being lysed in 10 mM Tris, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 2 mM Na3VO4, 0.1% Triton, 10% Glycerol, 1 mM PMSF, 0.5% Na-Deoxycholate, 20 mM Na2P2O7 and protease inhibitor (Roche). Cell lysates were centrifuged (1 h, 3200 rpm, 4°C) and the protein concentration was estimated by BCA™ assay (Pierce). The lysates were pre-cleared with A/G Plus Agarose beads (Santa Cruz, CA, USA) for 30 min at 4°C and incubated with total Fyn antibody (Santa Cruz) for 2 h in a rotary mixer following addition of A/G Plus Agarose beads for overnight incubation. Before performing SDS–PAGE and Western blot the immune complexes were washed extensively with NP-40 buffer and PBS. The precipitates were re-suspended in sample buffer, heated to 95°C for 5 min, and subjected to SDS–PAGE. Proteins were transferred to a PVDF membrane, blocked with bovine serum albumin and incubated with Y-418-phospho-Src (Biosource) antibody. Finally a horseradish-peroxidase conjugated secondary antibody was added and detected by ECL™ chemiluminescence (GE Healthcare UK Ltd) reagent on film. The optical density of the bands was estimated with NIH-Image J (free download at http://rsb.info.nih.gov/ij/) on digitized images.

RhoA GTPase activity assay

For the detection of active RhoA, OPCs were lysed (125 mM HEPES, pH 7.5, 750 mM NaCl, 5% Igepal CA-630, 50 mM MgCl2, 5 mM EDTA, 10% Glycerol, 25 mM NaF, 1 mM Na3VO4) according to the manufacturer’s instructions (Millipore Corporation) and active GTP-Rho was precipitated by the use of beads specific for the GST-binding domain (RBDD) of rhotekin. After removing cell debris the lysates were incubated with Rho Assay Reagent Slurry, which specifically binds GTP-Rho and not GTP-GDP (30 min, 4°C). Beads were then washed with Mg2+-lys/-wash buffer and bound material was eluted with 25 μl 2× Laemmli sample buffer, boiled for 5 min, resolved by SDS–PAGE and immunoblotted using mouse anti-RhoA antibody (3 μg/ml). Peroxidase-conjugated anti-mouse IgGs (GE Healthcare UK Ltd) were used as secondary antibodies. Immunoreactive proteins were visualized using ECL™ detection system (GE Healthcare UK Ltd). Densitometric analysis was performed using NIH-Image J software.

Statistical analysis

For all studies at least three independent experiments (n as detailed in results) were conducted and statistically assessed using Graph Pad Prism software (Graph Pad, San Diego, CA). To test the concentration dependent inhibition of OPC differentiation on MPE and the effect of various concentrations of pharmacological inhibitors one way ANOVA followed by Dunnett’s multiple comparison test was used. ROD values from Western blot following immunoprecipitation or pull-down assay were compared with Student-t-test.
Results

Soluble myelin molecules inhibit the differentiation of OPCs

To establish an in vitro assay for assessing the effects of myelin on OPC differentiation we adapted an approach previously reported by Robinson and Miller and plated neonatal OPCs on myelin substrates produced by incubation of myelin preparations on poly-L-lysine covered culture dishes (Robinson and Miller, 1999). The differentiation of oligodendrocyte lineage cells (OLCs) in vitro is characterized by distinct morphological and immunological features. Antibodies against O4 identify late OPCs by reacting with a sulphated glycolipid antigen named POA (Proligodendrocyte Antigen), while the same antibody also recognizes terminally differentiated OLCs by reacting with sulphated galactosylcerebroside (Bansal et al., 1989). The differentiation block mediated by presence of myelin is manifested as a reduction in O4-expression by OPCs (Robinson and Miller, 1999). In a previous study we showed that MPEs prepared with n-octyl-glycoside induce a concentration-dependent inhibition of differentiation in OPCs cultured in differentiation medium for 48 h similar to that observed with crude myelin membrane preparations (Syed et al., 2008). The inhibition of OPC differentiation is not only reflected by a reduction of O4 expression but also by a corresponding downregulation of mRNA expression for MBP, a late marker of mature oligodendrocytes, as assessed by qPCR (Fig. 1; n = 3). The presence of myelin was associated with a reduction in the complexity of OPC processes resulting in an increase of early OPC phenotypes with bipolar (stage I) morphology or primary branches (stage II) and a consecutive reduction of OPCs with secondary branched or membranous processes (stage III/IV) (Fig. 6) (one-way ANOVA P < 0.0001). We also confirmed previous data (Robinson and Miller, 1999) demonstrating that no changes occurred in the rate of cell proliferation as assessed by BrdU staining (no BrdU-positive cells were detected in the experimental groups) or apoptosis assessed by TUNEL assay, indicating that differences in the proportion of O4-positive cells reflect changes of cell differentiation and that these were not caused by an increase of OPC proliferation or differences in the rate of apoptosis (Supplementary Fig. 1).

Purification of inhibitory myelin fractions and proteomic analysis

The myelin proteins responsible for the inhibition of OPC differentiation are unknown. The most prominent myelin associated inhibitors (MAI) NogoA, MAG and Omgp do not affect OPC differentiation (Syed et al., 2008). To identify potential candidates we developed a column-chromatography fractionation protocol. In the first step MPE was submitted to a CM-column, and the resulting fractions tested by plating OPCs on the eluates. The fraction carrying inhibitory activity was then submitted to a second purification step using an ion exchange column (HighQ). The eluates obtained were tested in the same manner and the final inhibitory fraction was used for proteomic analysis.

To identify the protein species contained in the inhibitory fraction we employed a 3D gel-based separation protocol (BN-SDS-SDS) specifically tailored for identification of membrane-bound proteins (Kang et al., 2008). The protein spots on the 12 resulting gels were picked, digested and analysed on a nano-HPLC-ESI-Q-TOF mass spectrometer. The proteins identified are presented in Table 1 according to their annotation to the spots picked (Supplementary Fig. 2A–F). Of the 137 proteins detected, 18 were previously identified in proteomic analyses of myelin membrane fractions (Taylor and Pfeiffer, 2003; Taylor et al., 2004; Vanrobaeys et al., 2005; Werner et al., 2007). To confirm the presence of selected protein species we conducted Western blots on fractions generated as outlined above (Supplementary Fig. 3). These data provide a list of potential candidates that may be responsible for the inhibitory effect on OPC differentiation and illustrate the complexity of the myelin proteome, which becomes specifically apparent when highly abundant protein species are removed by column-chromatography based separation techniques.

Myelin impairs activation of the Src family tyrosine kinase Fyn-1

To investigate the basis of the myelin mediated inhibition of OPC differentiation we examined the activation of Src family tyrosine kinase Fyn-1. Several lines of evidence implicate an important role for Fyn-1 in the formation of myelin sheaths: first, the myelin content found in brains of fyn-deficient mice is reduced, and
Table 1  Identified protein list from BN/SDS/SDS–PAGE (3DE) from purified myelin protein fraction

| Protein Name                                      | Swiss-Prot ID | NCBI Acc. Noa | Theoretical molecular weight | No. of TMDb | Total ion-score | No. of matched peptides (MS/MS) | Sequence coverage (%) | Spot No. |
|--------------------------------------------------|---------------|---------------|-------------------------------|-------------|----------------|----------------------------------|------------------------|----------|
| **Known myelin proteins**                        |               |               |                               |             |                |                                  |                        |          |
| Myelin-associated glycoprotein precursor         | P07722        | gi|126685         | 69353                        | 1            | 294            | 8                                | 21                     | 18       |
| Myelin basic protein S                           | P02688        | gi|17378709       | 21546                        | 0            | 36             | 1                                | 5                      | 131      |
| Myelin-oligodendrocyte glycoprotein precursor    | Q63345        | gi|2497314        | 27882                        | 2            | 112            | 3                                | 13                     | 77       |
| Myelin proteolipid protein                       | P60203        | gi|14019153       | 30077                        | 4            | 124            | 3                                | 18                     | 3        |
| **Membrane proteins**                            |               |               |                               |             |                |                                  |                        |          |
| Abhydrolase domain-containing protein 6          | Q5X164        | gi|81883706       | 38312                        | 1            | 155            | 4                                | 13                     | 89       |
| Acyl-CoA-binding domain-containing protein 5      | A0FK17        | gi|123797828      | 56782                        | 1            | 59             | 1                                | 4                      | 58       |
| Basigin precursor                                | P26453        | gi|17042079       | 42436                        | 1            | 89             | 2                                | 5                      | 117      |
| Brain acid soluble protein 1                     | Q05175        | gi|730110         | 21790                        | 0            | 321            | 10                               | 41                     | 17       |
| CD9 antigen                                      | P40241        | gi|729088         | 25215                        | 4            | 239            | 7                                | 32                     | 2        |
| CD63 antigen                                     | P28648        | gi|113331         | 25699                        | 4            | 79             | 2                                | 11                     | 101      |
| CD81 antigen                                     | Q62745        | gi|11131474       | 25889                        | 4            | 211            | 5                                | 16                     | 4        |
| CD82 antigen                                     | O70352        | gi|9296930        | 29487                        | 4            | 45             | 2                                | 10                     | 21       |
| CD151 antigen                                    | Q9QZA6        | gi|11131479       | 28355                        | 4            | 160            | 4                                | 20                     | 51       |
| CD166 antigen precursor                          | O35112        | gi|76605356       | 21635                        | 1            | 194            | 6                                | 29                     | 74       |
| Cell adhesion molecule 2 precursor               | Q1WIM2        | gi|150438865      | 47528                        | 1            | 194            | 4                                | 11                     | 53       |
| Cell adhesion molecule 4 precursor               | Q1WIM1        | gi|123778954      | 42781                        | 1            | 193            | 6                                | 15                     | 28       |
| Cell cycle exit and neuronal differentiation protein 1 | Q5FV14 | gi|181882797 | 15043                        | 1            | 88             | 3                                | 23                     | 44       |
| Choline transporter-like protein 1               | Q8VI17        | gi|73918925       | 73092                        | 10           | 61             | 3                                | 4                      | 27       |
| Clathrin coat assembly protein AP180             | Q05140        | gi|2492686       | 93519                        | 0            | 96             | 3                                | 3                      | 92       |
| Claudin-11                                       | Q99P82        | gi|20332024      | 22046                        | 4            | 189            | 6                                | 37                     | 45       |
| Disks large-associated protein 2                 | P97837        | gi|71153508       | 118978                       | 0            | 164            | 6                                | 8                      | 34       |
| DnaJ homolog subfamily C member 5                | P60905        | gi|46397406      | 22101                        | 0            | 42             | 2                                | 11                     | 50       |
| Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 precursor | P84039 | gi|108862048 | 54290                        | 1            | 164            | 5                                | 12                     | 71       |
| Embigin precursor                                | O88775        | gi|61223483      | 37005                        | 1            | 176            | 5                                | 23                     | 72       |
| Erythropoietin receptor precursor                | Q07303        | gi|729431         | 55500                        | 1            | 88             | 4                                | 6                      | 94       |
| FXYD domain-containing ion transport regulator 6 precursor | Q91XV6 | gi|20138106 | 10388                        | 1            | 229            | 7                                | 26                     | 63       |
| FXYD domain-containing ion transport regulator 7 | P59649        | gi|30135809      | 8487                         | 1            | 38             | 1                                | 19                     | 5        |
| Golgin subfamily A member 2                      | Q62839        | gi|6226622       | 111428                       | 0            | 106            | 3                                | 4                      | 14       |
| Junctional adhesion molecule C precursor          | Q68FQ2        | gi|83286894     | 34783                        | 1            | 168            | 5                                | 16                     | 38       |
| Leukocyte surface antigen CD47 precursor         | P97829        | gi|76364105      | 32995                        | 5            | 69             | 3                                | 14                     | 33       |
| Limbic system-associated membrane protein precursor | Q62813    | gi|2497324       | 37324                        | 0            | 114            | 2                                | 7                      | 26       |
| Lysosome-associated membrane glycoprotein 1 precursor | P14562 | gi|1236738    | 43969                        | 1            | 225            | 5                                | 11                     | 16       |
| Lysosome-associated membrane glycoprotein 2 precursor | P17046 | gi|1236382 | 45591                        | 1            | 203            | 6                                | 17                     | 136      |
| Lysosome membrane protein 2                      | P27615        | gi|126291       | 54091                        | 2            | 268            | 12                               | 33                     | 22       |
| Major prion protein precursor                    | P13582        | gi|2507236       | 27804                        | 0            | 33             | 1                                | 7                      | 49       |
| Membrane transport protein XK                     | Q5GH61        | gi|77417634      | 51050                        | 10           | 133            | 4                                | 10                     | 23       |
| Metabotropic glutamate receptor 4 precursor      | P31423        | gi|400255        | 101819                       | 7            | 39             | 2                                | 1                      | 121      |
| Myosin-9                                         | Q62812        | gi|13431671      | 226338                       | 0            | 108            | 4                                | 2                      | 102      |
| Neural cell adhesion molecule 1, 140 kDa isoform precursor | P13596 | gi|127859 | 94658                        | 1            | 203            | 5                                | 6                      | 115      |

(continued)
| Protein Name                                      | Swiss-Prot ID | NCBI Acc. No.a | Theoretical molecular weight | No. of TMDb | Total ion-score | No. of matched peptides (MS/MS) | Sequence coverage (%) | Spot No. |
|--------------------------------------------------|---------------|----------------|-------------------------------|-------------|----------------|---------------------------------|----------------------|----------|
| Neurofilament medium polypeptide                 | P12839        | gi|128150  | 95791           | 0        | 110     | 4                             | 6                     | 128      |
| Neuromodulin                                     | P07936        | gi|128102  | 23603           | 0        | 116     | 3                             | 14                    | 110      |
| Neuroplastin precursor                           | P97546        | gi|1870588 | 31292           | 1        | 278     | 7                             | 36                    | 19       |
| Neurotrimin precursor                            | Q62718        | gi|1497325 | 37998           | 0        | 44      | 2                             | 7                     | 39       |
| Nisatin precursor                                | Q8CGU6        | gi|37081094 | 78400            | 1        | 332     | 12                            | 32                    | 15       |
| Neuritin precursor                               | O08957        | gi|1881220 | 15289           | 0        | 103     | 3                             | 10                    | 66       |
| Nuclear envelope pore membrane protein POM 121  | P52591        | gi|1709213 | 120785          | 1        | 226     | 5                             | 4                     | 80       |
| Opioid-binding protein/cell adhesion molecule precursor | F32736     | gi|1352640 | 38068           | 0        | 138     | 3                             | 11                    | 25       |
| Phosphatidylethanolamine-binding protein 1       | P31044        | gi|400734   | 20801           | 0        | 154     | 5                             | 21                    | 62       |
| Phospholemman precursor                         | O08589        | gi|22654268 | 10365            | 1        | 100     | 3                             | 19                    | 60       |
| Prostaglandin-H2 D-isomerase precursor           | P22067        | gi|1346697 | 21301           | 0        | 201     | 4                             | 16                    | 137      |
| Protocadherin Fat 2 precursor                   | O88277        | gi|22095688 | 480654          | 1        | 119     | 3                             | 6                     | 57       |
| Sodium channel protein type 9 subunit alpha      | O08562        | gi|55976160 | 226039          | 24       | 144     | 5                             | 2                     | 83       |
| Sodium channel subunit beta-2 precursor          | P54900        | gi|1705870 | 24145           | 1        | 121     | 4                             | 19                    | 36       |
| Sodium/potassium-transporting ATPase subunit beta-1 | P07340   | gi|114395  | 35202           | 1        | 88      | 3                             | 7                     | 56       |
| Synaptosomal-associated protein 23               | P88977        | gi|35439720 | 23315           | 0        | 114     | 3                             | 8                     | 67       |
| Synaptosomal-associated protein 25               | P60881        | gi|46397720 | 23315           | 0        | 114     | 3                             | 8                     | 67       |
| Syntaxin-18                                      | P61265        | gi|47117736 | 32345           | 1        | 188     | 6                             | 17                    | 64       |
| Tetraspanin-2                                    | Q9JJW1        | gi|13396887 | 24190           | 4        | 63      | 2                             | 8                     | 29       |
| Thioredoxin domain-containing protein C5orf14 homolog | Q5BLT4    | gi|1882519 | 37928           | 1        | 205     | 5                             | 8                     | 107      |
| Tyrosine-protein phosphatase non-receptor type substrate 1 precursor | P97710     | gi|29427383 | 55691           | 1        | 105     | 4                             | 10                    | 122      |
| Thy-1 membrane glycoprotein precursor            | P01830        | gi|135832  | 18172           | 0        | 99      | 3                             | 11                    | 130      |
| Voltage-dependent anion-selective channel protein 2 | P81155     | gi|46397780 | 31746           | 0        | 133     | 5                             | 14                    | 37       |
| 2,3’-cyclic-nucleotide 3’-phosphodiesterase       | P13233        | gi|51338709 | 47268           | 0        | 319     | 6                             | 13                    | 7        |
| Cytoplasmic proteins                             |               |               |                  |            |         |                                |                      |          |
| Amphiphysin                                       | O08838        | gi|14916529 | 74878           | 0        | 118     | 3                             | 5                     | 114      |
| Branched-chain-amino-acid aminotransferase, cytosolic | P54690    | gi|1705438 | 46046           | 0        | 226     | 7                             | 24                    | 98       |
| Calmodulin                                       | P62161        | gi|49037408 | 16838           | 0        | 125     | 3                             | 16                    | 111      |
| Coiled-coil domain-containing protein 93         | Q5BJT7        | gi|18188251 | 72636           | 0        | 152     | 4                             | 6                     | 104      |
| COP9 signalosome complex subunit 1              | P57834        | gi|2494624 | 53428           | 0        | 108     | 4                             | 9                     | 24       |
| ERC protein 2                                    | Q8K3M6        | gi|51701368 | 110618          | 0        | 98      | 2                             | 3                     | 42       |
| FKB12-rapamycin complex-associated protein       | P42346        | gi|1169736 | 288794          | 0        | 68      | 2                             | 1                     | 87       |
| Gial fibrillary acidic protein                    | P47819        | gi|11531597 | 49957           | 0        | 113     | 3                             | 10                    | 31       |
| Glutathione transferase omega-1                  | Q92339        | gi|12585231 | 27669          | 0        | 113     | 3                             | 9                     | 106      |
| Heat shock cognate 71 kDa protein                | P63018        | gi|15702273 | 70871           | 0        | 271     | 5                             | 6                     | 135      |
| Huntington                                       | P91111        | gi|1708162 | 343762          | 0        | 101     | 3                             | 1                     | 91       |
| Hypoxanthine-guanine phosphoribosyltransferase   | P27605        | gi|123501  | 24477           | 0        | 32      | 1                             | 4                     | 124      |
| Junction plakoglobin                             | Q6P0K8        | gi|1885083 | 81801           | 0        | 105     | 4                             | 5                     | 41       |
| LAMA-like protein 2 precursor                    | Q4QQW2        | gi|146324999 | 65456          | 0        | 201     | 5                             | 9                     | 90       |
| Myc box-dependent-interacting protein 1          | O08839        | gi|14916534 | 64533           | 0        | 229     | 8                             | 12                    | 113      |
| NAD-dependent deacetylase sirtuin-2              | Q5RJQ4        | gi|18883338 | 39319           | 0        | 91      | 2                             | 5                     | 109      |
| Protein Name                                                                 | Accession   | gi| Length | PID  | M  | T  | Score|
|----------------------------------------------------------------------------|-------------|---|--------|------|----|----|------|
| Neurocalcin-delta                                                          | Q5PQN0      | 1 | 22245  | 0    | 126| 4  | 20   |
| Neuron-specific calcium-binding protein hippocalcin                       | P84076      | 2 | 22427  | 0    | 98 | 4  | 23   |
| Glycosyltransferase GLT28D1                                                | Q5I0K7      | 3 | 18329  | 0    | 62 | 2  | 7    |
| Phenylalanyl-tRNA synthetase alpha chain                                   | Q505J8      | 4 | 57720  | 0    | 88 | 2  | 5    |
| Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A                      | Q9JMC1      | 5 | 107208 | 0    | 97 | 4  | 3    |
| Protein kinase C and casein kinase substrate in neurons protein 1          | Q9Z0W5      | 6 | 50449  | 0    | 114| 5  | 14   |
| Protein S100-A3                                                            | P62819      | 7 | 11747  | 0    | 52 | 1  | 14   |
| Protein S100-A6                                                            | P05964      | 8 | 10035  | 0    | 89 | 2  | 28   |
| Protein S100-B                                                             | P04631      | 9 | 10744  | 0    | 98 | 3  | 18   |
| Superoxide dismutase [Cu-Zn]                                               | P07632      | 10| 15912  | 0    | 106| 2  | 13   |
| Thioredoxin                                                                | P11232      | 11| 11673  | 0    | 135| 4  | 24   |
| Tropomyosin alpha-1 chain                                                  | P04692      | 12| 32681  | 0    | 88 | 2  | 6    |
| Tropomyosin alpha-3 chain                                                  | Q63610      | 13| 29007  | 0    | 76 | 2  | 7    |
| Ubiquitin carboxyl-terminal hydrolase 19                                   | Q6J1Y9      | 14| 150302 | 0    | 119| 6  | 3    |
| UDP-glucose:glycoprotein glucosyltransferase 1 precursor                  | Q9JLA3      | 15| 174049 | 0    | 157| 3  | 2    |
| Visinin-like protein 1                                                     | P62762      | 16| 22142  | 0    | 213| 6  | 31   |
| 14-3-3 protein zeta/delta                                                  | P63102      | 17| 27771  | 0    | 228| 7  | 28   |
| Nuclear proteins                                                           |             |   |        |      |    |    |      |
| Calpain-5                                                                  | Q8R4C0      | 18| 73065  | 0    | 155| 5  | 10   |
| Cell division cycle 5-related protein                                      | O08837      | 19| 92218  | 0    | 33 | 3  | 3    |
| DNA repair protein RAD50                                                   | Q9JL8       | 20| 153784 | 0    | 223| 5  | 3    |
| Histone H2B type 1                                                         | Q00715      | 21| 13990  | 0    | 123| 3  | 21   |
| Histone H2B type 1-A                                                       | Q00729      | 22| 14225  | 0    | 109| 2  | 26   |
| Histone H3.1                                                               | Q6LE0D      | 23| 15404  | 0    | 49 | 1  | 8    |
| Histone H4                                                                 | P62804      | 24| 11367  | 0    | 102| 3  | 34   |
| La-related protein 7                                                        | Q5X101      | 25| 64949  | 0    | 32 | 3  | 10   |
| RING finger protein 18                                                      | Q6AXU4      | 26| 19288  | 0    | 34 | 2  | 9    |
| Small ubiquitin-related modifier 2 precursor                              | P61959      | 27| 10871  | 0    | 76 | 3  | 13   |
| Structural maintenance of chromosomes protein 3                            | P97690      | 28| 138448 | 0    | 149| 4  | 3    |
| UV excision repair protein RAD23 homolog B                                  | Q4KMA2      | 29| 43497  | 0    | 133| 4  | 7    |
| Vimentin                                                                   | P31000      | 30| 53733  | 0    | 251| 6  | 14   |
| Zinc finger CCCH type antiviral protein 1                                   | Q8K3Y6      | 31| 86771  | 0    | 100| 4  | 7    |
| Secreted proteins                                                          |             |   |        |      |    |    |      |
| Alpha-1-antiproteinase precursor                                           | P17475      | 32| 46136  | 0    | 164| 5  | 19   |
| Apolipoprotein D precursor                                                 | P23593      | 33| 21635  | 0    | 162| 5  | 25   |
| C-reactive protein precursor                                               | P48199      | 34| 25468  | 0    | 65 | 3  | 17   |
| Serine protease inhibitor A3K precursor                                    | P05545      | 35| 46562  | 0    | 211| 6  | 16   |
| Serine protease inhibitor A3L precursor                                    | P05544      | 36| 46277  | 0    | 206| 5  | 16   |
| Sulfated glycoprotein 1 precursor                                          | P10960      | 37| 61124  | 0    | 264| 5  | 10   |
| Transthyretin precursor                                                   | P02767      | 38| 15720  | 0    | 76 | 2  | 10   |
| Extracellular proteins                                                      |             |   |        |      |    |    |      |
| Annexin A8                                                                 | Q4FZU6      | 39| 36706  | 0    | 151| 4  | 15   |
| Hemoglobin subunit alpha-1/2                                               | P01946      | 40| 15329  | 0    | 255| 7  | 39   |
| Hemoglobin subunit beta-1                                                  | P02091      | 41| 16083  | 0    | 245| 8  | 36   |

(continued)
second, Fyn-1 can be co-immuno-precipitated from brain lysates with antibodies to MAG (Umemori et al., 1994). More recent data suggest that activation of Fyn-1 is one of the earliest events triggered in differentiating OPCs and that Fyn-1 tyrosine kinase regulates process extension and myelin sheath formation (Osterhout et al., 1999; Colognato et al., 2004).

Protein extracts from OPCs plated on MPE cultured in differentiation medium for 24 h were compared with protein extracts from OPCs plated on control substrates under the same conditions by immunoprecipitation with anti-Fyn-1 and immunoblotting with anti-Src Y-418, to detect phosphorylation at the activation site of Fyn-1. The results demonstrated a clear impairment of Fyn-1 activation in cells plated on MPE (n = 4; t-test: P = 0.0003; Fig. 2A and B). In OPCs plated on control substrate phosphorylation of Fyn-1 increased over time as previously reported (Osterhout et al., 1999).

Myelin molecules mediate inhibitory signals via activation of RhoA

Fyn-1 kinase regulates the activity of the small GTPase RhoA (Colognato et al., 2004), which, along with other Rho GTPase subfamily members is an important regulator of oligodendrocyte morphology (Mi et al., 2005; Thurnherr et al., 2006). Overexpression of dominant-negative RhoA causes hyperextension of oligodendrocyte processes (Wolf et al., 2001) while a reduction of active RhoA-GTP is necessary for successful oligodendrocyte differentiation (Liang et al., 2004). To assess activation of RhoA in OPCs cultured on MPE and control substrates for 24 h in differentiation medium we performed a RhoA-GTP-pull down assay followed by Western blot for RhoA. Our data show that the presence of myelin inhibitors induces an increase of GTP bound RhoA (n = 3; t-test: P = 0.0113; Fig. 2C and D).

To assess the functional role of RhoA in mediating inhibitory effects of MAI to OPC differentiation we transfected OPCs with siRNA specifically directed against RhoA. Cells were transfected with high efficiency (>95%). This induced a marked down-regulation of the expression of RhoA as assessed by Western blot. The reduction of RhoA powerfully triggered OPC differentiation in the presence of MPE (Fig. 5; n = 3; mean increase = 233%; ANOVA: P < 0.0001, Dunnett’s post-test MPE versus siRNA: P < 0.0001) confirming the importance of RhoA in mediating the inhibitory effects as well as indicating that these can be beneficially modulated by inhibiting RhoA signalling in OPCs.

Inhibition of ROCK-II induces differentiation of OPCs in the presence of myelin

Rho kinases (ROCK) are important effector proteins of RhoA and phosphorylate a number of downstream molecules that regulate actin filaments (Riento and Ridley, 2003). Since ROCK-II is the isomor predominantly expressed in the CNS, we hypothesized its participation in transducing myelin derived inhibitory signals in OPCs. We first confirmed ROCK-II expression in OPCs by Western blot analysis and then examined its functional role.
by plating OPCs on MPE and adding different concentrations of the ROK\textsubscript{II}-inhibitor HA-1077 (Fasudil) to the differentiation medium (Fig. 3). Treatment with HA-1077 for 48 h resulted in a dramatic increase in the number of differentiating OPCs ($n=4$; mean increase at 5$\mu M$ = 174%; ANOVA: $P<0.0001$, Dunnett’s post tests MPE versus 5 and 10$\mu M$: $P<0.001$). To exclude changes in cell survival we conducted TUNEL assays which showed no significant differences between OPCs plated on PLL and cells plated on MPE treated with HA-1077 (Supplementary Fig. 1).

Thus, we conclude that RhoA-ROCK signalling plays an important role in mediating myelin derived inhibitory effects in differentiating OPCs that can be beneficially modulated by the use of pharmacological inhibitors and siRNA-mediated gene silencing.

Myelin inhibitors retain Myristoylated, alanine-rich C-kinase substrate within the cytosolic compartment

PKC has also been implicated in OPC differentiation since PKC activation mimicked by the phorbol ester PMA inhibits OPC differentiation (Baron \textit{et al}., 1998) while at late stages of OPC differentiation, PKC may also facilitate process extension and expression of myelin proteins (Althaus \textit{et al}., 1991; Yong \textit{et al}., 1991; Asotra and Macklin, 1993; Stariha and Kim, 2001). Myristoylated, alanine-rich C-kinase substrate (MARCKS) is a substrate of PKC that has been used as an indirect marker for PKC activation in OPCs (Baron \textit{et al}., 1999). Inhibitory PKC mediated signalling is associated with phosphorylation and membrane-to-cytosol translocation of MARCKS (Baron \textit{et al}., 1999) and may cause disorganization of the cytoskeleton and redistribution of actin filaments (Baron \textit{et al}., 1998, 1999). MARCKS has been implicated in several cellular processes such as secretion, phagocytosis, cell motility, membrane traffic, growth suppression and regulation of the cell cycle as well as OPC differentiation (Baron \textit{et al}., 1998, 1999; Arbuzova \textit{et al}., 2002). Phosphorylated MARCKS is translocated from the plasma membrane to the cytosol (Wang \textit{et al}., 1989; Thelen \textit{et al}., 1991; Byers \textit{et al}., 1993; Allen and Aderem, 1995). To detect changes in theintracellular distribution of MARCKS OPCs plated on MPE and control-PLL stained for A2B5 and MARCKS were compared using a laser scanning microscope (Fig. 4A–F). In differentiating OPCs MARCKS was distributed to the cell membrane whereas in OPCs in which differentiation was inhibited by the presence of MPE a clear cytosolic presence of MARCKS was detected supporting the notion that PKC is activated by myelin and that myelin inhibitors modulate cytoskeletal dynamics by MARCKS.
PKC inhibitors promote OPC differentiation in the presence of myelin inhibitors

In order to test whether inhibition of PKC signalling is able to modulate the myelin-mediated differentiation block OPCs plated on myelin were treated with the two selective PKC inhibitors, BIM (Bisindolylmaleimide IX, Methasulfonate Salt) and Gö6976. We found that treatment with BIM (n=4; mean increase at 6.25 nM = 169%; ANOVA: \(P < 0.0001\), Dunnett’s post tests) and even more so with Gö6976 (n=3; mean increase at 50 nM = 267%; ANOVA: \(P < 0.0001\), Dunnett’s post-test) strongly induced OPC differentiation after 48 h incubation in differentiation medium. (Scalebar: in A–C: 15.9 μm, in D–F: 14.6 μm in H–J, L–N: 30 μm).

Fig. 4 (A–F) MARCKS is a down-stream effector of PKC. While in control cells MARCKS expression is associated with the cell membrane, myelin inhibitors lead to a cytoplasmatic MARCKS presence. (G–N) Inhibition of PKC signalling in OPCs on MPE with BIM (G–J; max. mean increase 169%) or Gö6976 (K–N; max. mean increase 269%) strongly induces OPC differentiation after 48 h incubation in differentiation medium. (Scalebar: in A–C: 15.9 μm, in D–F: 14.6 μm in H–J, L–N: 30 μm).
50 nM: \( P < 0.001 \) was able to stimulate OPC differentiation in the presence of myelin (Fig. 4G–N). TUNEL assays showed no differences in the rate of apoptosis between control cells and OPCs plated on myelin treated with Bim or Go6976 (Supplementary Fig. 1). As the use of pharmacological inhibitors entails the risk of regulating cascades other than the targeted, we used siRNA to down-regulate PKC-\( \gamma \) expression in OPCs plated on myelin (Fig. 5). SiRNA-mediated silencing of PKC-\( \gamma \) was successful and cells transfected displayed a marked decrease of PKC-\( \gamma \) at protein level. The reduction of PKC-\( \gamma \) potently induced OPC differentiation on MPE confirming the validity of the pharmacological approach (\( n = 3; \) mean increase = 232%; ANOVA: \( P < 0.0001 \), Dunnett’s post test MPE versus siRNA: \( P < 0.0001 \)) (Fig. 5).

Blocking both ROCK-II and PKC further promotes OPC differentiation

We next investigated whether ROCK-II and PKC transduce inhibitory signals via common or separate mechanisms and whether blocking both pathways at the same time could further promote OPC differentiation in the presence of myelin inhibitors. Treatment with Fasudil and Go6976 simultaneously induced a further increase of the percentage of differentiating OPCs (Fig. 6; t-test: HA-1077 versus co-incubation: \( P = 0.0288 \)). Furthermore, the treatment of OPCs on MPE with the inhibitors was able to reverse the effects of myelin on OPC morphology and resulted in the presence of more mature phenotypes (stages III and IV, Fig. 6; ANOVA of early stages (I/II) in PLL, MPE, and co-treatment \( P = 0.0027 \); Dunn post-test: MPE versus co-treatment \( P < 0.01 \)). MPE may not include all inhibitory factors present in crude myelin preparations. To ensure that the beneficial treatment effects were not restricted to substrates prepared with MPE we incubated OPCs plated on crude myelin preparations with HA-1077, Go6976, or a combination of both. This resulted in a similar induction of OPC differentiation in the presence of myelin inhibitors (data not shown). Taken together our findings suggest that the inhibitory effects of myelin molecules are mediated by at least two independent pathways. Furthermore, blocking both pathways simultaneously may provide an even more potent strategy to improve OPC differentiation in an in vivo setting.

Discussion

Axonal integrity is tightly coupled with myelin function as subtle changes in the molecular composition can result in mid- to long term axonal degeneration under otherwise physiological conditions (Griffiths et al., 1998; Garbern et al., 2002; Lappe-Siefke et al., 2009).
The trophic function of myelin sheaths is also very likely to be of significance for maintaining axonal integrity in both acute and chronic CNS pathology, a situation in which denuded axons may be more prone to injury or degeneration than axons bearing functionally intact myelin sheaths. Thus increasing efforts have been placed in the development of strategies by which remyelination may be enhanced therapeutically (Dubois-Dalcq et al., 2005).

Although much is known about the biology of OPCs attempts to stimulate remyelination in vivo by increasing or modulating the expression proliferation or differentiation inducing factors have not been universally successful, especially when older adult animals are used in which myelin debris clearance is poor and remyelination inefficient (Shields et al., 1999; O’Leary et al., 2002; Sim et al., 2002; Penderis et al., 2003; Ibanez et al., 2004; Woodruff et al., 2004). The presence of inhibitory molecules in myelin debris generated as a consequence of oligodendrocyte degeneration may in part provide an explanation for the so far generally frustrating failure of these different strategies (Kotter et al., 2006).

The key aim of our study was to examine the mechanisms that control the myelin mediated inhibition of OPC differentiation. The myelin molecules blocking OPC differentiation remain unknown. However, it is a plausible hypothesis that these molecules expressed on mature oligodendrocytes provide a feed-back inhibition for early (A2B5+) precursor cells. Under normal physiological situations this feed-back system may serve to prevent inappropriate differentiation of OPCs in normal adult white matter (Robinson and Miller, 1999), while in development one might speculate that signalling from mature oligodendrocytes to early precursors may play a functional role in regulating OPC differentiation. The situation following demyelination entails profound environmental changes as large amounts of degenerated myelin can accumulate within lesions. In experimental models this is efficiently cleared by macrophages of microglial and monocytic origin (Kotter et al., 2001, 2005). However, it is conceivable that if clearance of myelin debris is disturbed by alterations of the inflammatory response the presence of myelin debris can persist and thus for a prolonged period inhibit myelin repair. Recent studies suggest that remyelination requires the signalling environment provided by an acute inflammatory response (Mason et al., 2001; Foote and Blakemore, 2005; Kotter et al., 2005; Setzu et al., 2006). Therefore, it could be speculated that a situation may occur in which the initial inclination OPCs to differentiate is inhibited by the presence of myelin and turns into reluctance as the expression of signalling molecules required to activate OPCs diminishes.

The cascades that we found to be modulated by the presence of myelin inhibitors are similar to the ones that regulate the inhibition of axon growth via NogoR and Lingo-1 signalling (Lee et al., 2004; Mi et al., 2005). However, there is no evidence that
NogoR is expressed by OPCs and we ourselves were not able to detect NogoR expression in our cultures. While immunocytochemistry for Lingo-1 is inconclusive we found evidence of Lingo-1 mRNA in cultured OPCs (unpublished data). Furthermore, we have not seen evidence of an inhibitory effect of any of the classical myelin inhibitors of axon growth on OPC differentiation (Syed et al., 2008). Thus the molecular substrate present in myelin mediating the inhibitory effects remains unknown.

In this study, we developed a biochemical and proteomic protocol to identify potential candidates responsible for the myelin differentiation block. With the criteria we applied this resulted in a list of 137 myelin proteins—18 of which were previously identified using a proteomic approach. The detection of so many previously unidentified proteins in myelin can be explained in part by the biochemical separation process we developed, which removes many of the most abundant proteins. On the other hand, we applied a gel-based separation technique that is specifically tailored for the study of membrane-bound proteins that has not been previously used for the analysis of the myelin proteome. To identify the myelin protein(s) responsible for the inhibition of OPC differentiation further separation steps may be helpful. However, stringent data assessment may help to narrow down the list of potential candidates. Apart from providing a list of potential candidates our data illustrates the complexity of myelin and will provide a reference for further studies of the biology of myelin membranes.

Our results provide a model of how myelin exerts inhibitory effects on OPC differentiation. In inhibiting RhoA-ROCK and PKC(-α) signalling we have identified pharmacological targets by which OPC differentiation can be powerfully stimulated in the context of myelin inhibitors.

Fasudil is currently evaluated in a clinical setting for treatment of vasospasm as well as angina pectoris in humans (Vicari et al., 2005). Similarly, a number of clinical studies investigate the effects of PKC inhibitors in cancer (Mackay and Twelves, 2007). While it has to be expected that not all inhibitors can pass the brain blood barrier, a number of PKC inhibitors (e.g. Tamoxifen, Calphostin-C, HA-1004 and Ro 32-0432) (Gozal et al., 1998; Cerezo et al., 2002; Zarate et al., 2007) as well as Rho-cascade inhibitors (e.g. Fasudil) are able to cross the brain blood barrier (Satoh et al., 2008). PKC and ROCK inhibition have shown to exert stimulating effects on neurite outgrowth in the presence of myelin inhibitors, and thus synergistic effects with respect to neural repair could be expected (Sivasankaran et al., 2004). As far as effects on other cell types are concerned, inhibition of PKC in microglia is associated with e.g. downregulation of MHC-II (Nikodemova et al., 2007), a reduction of proinflammatory cytokine, iNOS (Kang et al., 2001; Min et al., 2004), and TNF-α release (Jeohn et al., 2002) in response to various inflammatory modulators including LPS, ganglioside and IFNγ suggesting a reduction of proinflammatory activity in microglia. On the other hand, it has been reported that PKC inhibition lead to reduced CR3/Mac-1 and SRAI/II mediated myelin phagocytosis (Cohen et al., 2006) which may be relevant to myelin repair although the mechanisms we report aim at neutralizing the effects of MAI on OPC differentiation.

Astrocytes react upon PKC inhibition by e.g. decreased activation of ATP-mediated glutamate outwards channels (Rudkouskaya et al., 2008) and TGFβ1 production (Wang et al., 2003), furthermore, the response to LPA is altered by a reduced proproliferative intracellular Ca2+ increase (Keller et al., 1997) and NGF secretion (Furukawa et al., 2007). It is difficult to interpret these findings in the light of remyelination as little is known about the molecular events in astrocytes during myelin repair. However, it seems unlikely that the effects of PKC inhibition on astrocytes reported will negatively impact remyelination.

Under the influence of Fasudil rat astrocytes transform in vitro into process bearing cells (Abe and Misawa, 2003) which can be explained by direct effects of the Rho-cascade on the cytoskeleton, on the other hand there are no data available how changes in astrocyte processes impact myelin repair.

Finally, little is known of how microglia react to inhibition of the Rho-cascade. A recent paper suggests that inhibition of RhoA by C3 induces NO and proinflammatory cytokine release, however, this is independent of ROCK signalling and was instead found to be under the control of NFκB suggesting that targeting down-stream signalling events may circumvent problems that may arise as a consequence of microglia activation (Hoffmann et al., 2008).

Our data suggest that inhibiting PKC and/or Rho-signalling would be beneficial either acutely following demyelination, where exposure to myelin debris that has yet to be cleared might critically interrupt the initiation of remyelination resulting in its long term failure or in chronic disease where OPCs remain exposed to a differentiation-inhibitory environment. The data in the current study paves the way for subsequent testing of pharmacological interventions in animal models and further clinical evaluation if the outcome were to be successful.

### Supplementary material

Supplementary material is available at Brain online.

### Acknowledgements

We especially thank Thomas Dalik for excellent technical support.

### Funding

Medical University Vienna; FWF Austrian Science Funds.

### References

Abe K, Misawa M. Astrocyte stellation induced by Rho kinase inhibitors in culture. Brain Res Dev Brain Res 2003; 143: 99–104.

Allen LA, Aderem A. Protein kinase C regulates MARCKS cycling between the plasma membrane and lysosomes in fibroblasts. EMBO J 1995; 14: 1109–21.

Althaus HH, Schrotter J, Spoerri P, Schwartz P, Kloppner S, Rohmann A, et al. Protein kinase C stimulation enhances the process formation of
adult oligodendrocytes and induces proliferation. J Neurosci Res 1991; 29: 481–9.
Alvarez-Buylla A, Lois C. Neuronal stem cells in the brain of adult vertebrates. Stem Cells 1995; 13: 263–72.

Arbuzova A, Schmitz AA, Vergeres G. Cross-talk unfolded: MARCKS proteins. Biochem J 2002; 362: 1–12.

Asotra K, Macklin WB. Protein kinase C activity modulates myelin gene expression in enriched oligodendrocytes. J Neurosci Res 1993; 34: 571–88.

Back SA, Tuohy TM, Chen H, Wallingford N, Craig A, Struve J, et al. Hyaluronic accumulates in demyelinated lesions and inhibits oligoden-
drocyte progenitor maturation. Nat Med 2005; 11: 966–72.

Baron W, Warrington AE, Gard AL, Ranscht B, Pleiffer SE. Multiple and novel specificities of monoclonal antibodies O1, O4, and R-mAb used in the analysis of oligodendrocyte development. J Neurosci Res 1989; 24: 548–57.

Baron W, de Jonge JC, de Vries H, Hoekstra D. Regulation of oligoden-
drocyte differentiation: protein kinase C activation prevents differen-
tiation of O2A progenitor cells toward oligodendrocytes. Glia 1998; 22: 121–9.

Baron W, de Vries EJ, de Vries H, Hoekstra D. Protein kinase C prevents oligodendrocyte differentiation: modulation of actin cytoskeleton and cognate polarized membrane traffic. J Neurobiol 1999; 41: 385–98.

Blakemore WF, Franklin RJ. Remyelination in experimental models of
toxin-induced demyelination. Curr Top Microbiol Immunol 2008; 318: 193–212.

Byers DM, Palmer FB, Spence MW, Cook HW. Dissociation of phosphor-
ylation and translocation to a myristoylated protein kinase C substrate (MARCKS protein) in C6 glioma and N1E-115 neuroblastoma cells. J Neurochem 1993; 60: 1414–21.

Carroll WM, Jennings AR, Ironside JJ. Identification of the adult resting progenitor cell by autoradiographic tracking of oligodendrocyte precursors in experimental CNS demyelination. Brain 1998; 219: 293–302.

Cerezo M, Laorden ML, Milanes MV. Inhibition of protein kinase C but not protein kinase A attenuates morphine withdrawal excitation of rat hypothalamus-pituitary-adrenal axis. Eur J Pharmacol 2002; 452: 57–66.

Chang A, Nishiyama A, Peterson J, Primeas J, Trapp BD. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci 2000; 20: 6404–12.

Charles P, Reynolds R, Seilhan D, Rougon G, Aigrot MS, Niezgoda A, Blakemore WF, Franklin RJ. Remyelination in experimental models of
toxin-induced demyelination. Curr Top Microbiol Immunol 2008; 318: 193–212.

Colognato H, Ramachandrapa S, Olsen IM, Ffrench-Constant C. Integrins direct Src family kinases to regulate distinct phases of oligoden-
drocyte development. J Cell Biol 2004; 167: 365–75.

De Vries J, de Vries EJ, de Vries H, Hoekstra D. Neuronal stem cells in adult rat optic nerve. Nature 1986; 319: 499–502.

Dubois-Dalcq M, Ffrench-Constant C, Franklin RJ. Enhancing central ner-
drocyte development. J Cell Biol 2004; 167: 365–75.

Engler AJ, Sen CK, Sweeney PA, Oppermann U, Sweeney CJ, et al. Conserved helical modules of portal complexes by mass spectrometry-
involved in interferon-gamma-induced expression of inducible nitric
oxide synthase in murine BV2 microglia. Neurosci Lett 2001; 299: 205–208.

Etienne-Griffiths M, Stochaj U, Hameen-Aho MM, Yilmaz A, Potschka H, et al. Multiple sclerosis: re-expression of a developmental pathway of Rho-dependent pathways by Clostridium botulinum C3 protein induces a proinflammatory profile in microglia. Glia 2008; 56: 1162–75.

Franklin RJM. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci 2002; 3: 705–14.

Furukawa A, Kita K, Toyomoto M, Fuji S, Inoue S, Hayashi K, et al. Production of nerve growth factor enhanced in cultured mouse astro-
cytes by glycerophospholipsids, sphingolipids, and their related com-
bounds. Mol Cell Biochem 2007; 305: 27–34.

Garbern JY, Yool DA, Moore GJ, Wilds IB, Faulk MW, Klugmann M, et al. Patients lacking the major CNS myelin protein, proteolipid pro-
tein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 2002; 125: 551–61.

Gensert JM, Goldman JE. Endogenous progenitors remyelinate demyelin-
atized axons in the adult CNS. Neurosci 1997; 19: 197–203.

Gozal E, Roussel AL, Holt GA, Gozal L, Gozal YM, Torres JE, et al. Protein kinase C modulation of ventilatory response to hypoxia in
nucleus tractus solitarii of conscious rats. J Appl Physiol 1998; 84: 1982–90.

Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998; 280: 1610–3.

Hoffmann A, Hofmann F, Just I, Lehnardt S, Hanisch UK, Bruck W, et al. Inhibition of Rho-dependent pathways by Clostridium botulinum C3 protein induces a proinflammatory profile in microglia. Glia 2008; 56: 1162–75.

Horner PJ, Power AE, Kempermann G, Kuhn HG, Palmer TD, Winkler J, et al. Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J Neurosci 2000; 20: 2218–28.

Ibanez C, Shields SA, El Etr M, Baulieu EE, Schumacher M, Franklin RJM. Systemic progesterone administration results in a partial reversal of the age-associated decline in CNS remyelination following toxin-induced demyelination in male rats. Neuropathol Appl Neurobiol 2004; 30: 80–9.

Jehon GH, Cooper CL, Jiang KJ, Liu B, Lee DS, Kim HC, et al. Go6976 inhibits LPS-induced microglial TNFalpha release by suppressing p38 MAP kinase activation. Neuroscience 2002; 114: 689–97.

John GR, Shankar SL, Shaft-Zagardo B, Massimi A, Raine CS, et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 2002; 8: 1115–21.

Kang J, Yang M, Jou I, Joe E. Identification of protein kinase C isoforms involved in interferon-gamma-induced expression of inducible nitric oxide synthase in murine BV2 microglia. Neurosci Lett 2001; 299: 205–208.

Kang S, Poliakov A, Sexton J, Renfrow MB, Prevelige PE Jr. Probing conserved helical modules of portal complexes by mass spectrometry-
based hydrogen/deuterium exchange. J Mol Biol 2008; 381: 772–84.

Keller JN, Steiner MR, Holtsberg FW, Mattson MP, Steiner SM. Lysophosphatidic acid-induced proliferation-related signals in astro-
cyes. J Neurochem 1997; 69: 1073–84.

Kotter MR, Li WW, Zhao C, Franklin RJM. Myelin Impairs CNS remye-
lination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci 2006; 26: 328–32.

Kotter MR, Setzu A, Sim FI, Van Rooijen N, Franklin RJM. Macrophage depletion impairs oligodendrocyte remyelination following lyssolecithin-
duced demyelination. Glia 2001; 35: 204–12.

Kotter MR, Zhao C, Van Rooijen N, Franklin RJM. Macrophage depletion-induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 2005; 18: 166–75.

Kuhlmann T, Miron V, Cuo Q, Wegner C, Antel J, Bruck W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 2008; 131 (Pt 7): 1749–58.

Lappe-Siefke C, Goebels S, Gravel M, Strittmatter M, Nicksch E, Lee J, Braun PE, et al. Inhibition of Rho-dependent pathways by Clostridium botulinum C3 protein induces a proinflammatory profile in microglia. Glia 2008; 56: 1162–75.

Liang X, Draghi NA, Resh MD. Identification from linglins to Fyn to Rho family GTpases regulates morphologic differentiation of oligodendro-
cytes. J Neurosci 2004; 24: 7140–9.

Mackay HJ, Twelves CJ. Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 2007; 7: 554–62.

Mason JL, Suzuki K, Chaplin DD, Matsuhasha GK. Interleukin-1beta promotes repair of the CNS. J Neurosci 2001; 21: 7046–52.

McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 1980; 85: 890–902.

Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z, et al. LINCO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005; 8: 745–51.
Min KJ, Pyo HK, Yang MS, Ji KA, Jou I, Joe EH. Gangliosides activate microglia via protein kinase C and NADPH oxidase. Glia 2004; 48: 197–206.

Nave KA, Trapp BD. Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 2008; 31: 535–61.

Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII. J Biol Chem 2007; 282: 15208–16.

Norton WT, Poduslo SE. Myelination in rat brain: method of myelin isolation. J Neurochem 1973; 21: 749–57.

Nunes MC, Roy NS, Keyoung HM, Goodman RR, McKhann G, Jiang L, et al. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med 2003; 9: 439–47.

O’Leary MT, Hinks GL, Franklin RJM. Increasing local levels of IGF-1 mRNA expression using adeno viral vectors does not alter oligodendrocyte remyelination in the CNS of aged rats. Mol Cell Neurosci 2002; 19: 32–42.

Osterhout DJ, Wolven A, Wolf RM, Resh MD, Chao MV. Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase. J Cell Biol 1999; 145: 1209–18.

Patani R, Balaratnam M, Vora A, Reynolds R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol Appl Neurobiol 2007; 33: 277–87.

Patrikios P, Stadelmann C, Kutzelinga A, Rauschka H, Schmidbauer M, Lausen H, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129: 3165–72.

Penderis J, Woodruff RH, Lakatos A, Li WW, Dunning MD, Zhao C, et al. Increasing local levels of neuregulin (glial growth factor-2) by direct infusion into areas of demyelination does not alter remyelination in the rat CNS. Eur J Neurosci 2003; 18: 2253–64.

Reynolds BA, Weiss S. Central nervous system growth and differentiation factors: clinical horizons–truth or dare? Curr Opin Biotechnol 1993; 4: 734–8.

Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003; 4: 446–56.

Robinson S, Miller RH. Contact with central nervous system myelin inhibits oligodendrocyte progenitor maturation. Dev Biol 1999; 216: 359–68.

Rudkouskaya A, Chernoguz A, Haskew-Layton RE, Mongin AA. Two conventional protein kinase C isoforms, alpha and betaI, are involved in the ATP-induced activation of volume-regulated anion channel and glutamate release in cultured astrocytes. J Neurochem 2008; 105: 2260–70.

Satoh S, Toshima Y, Hitomi A, Ikegaki I, Seto M, Asano T. Wide therapeutic window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. Brain Res 2008; 1193: 102–8.

Setzu A, Lathia JD, Zhao C, Wells K, Rao MS, Ffrench-Constant C, et al. Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells. Glia 2006; 54: 297–303.

Shields SA, Gilson JM, Blakemore WF, Franklin RJM. Remyelination occurs as extensively but more slowly in old rats compared to young rats following glutoxin-induced CNS demyelination. Glia 1999; 28: 77–83.

Sim FI, Zhao C, Penderis J, Franklin RJM. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 2002; 22: 2451–9.

Sivasankaran R, Pei J, Wang KC, Zhang YP, Shields CB, Xu XM, et al. PKC mediates inhibitory effects of myelin and chondroitin sulfate proteoglycans on axonal regeneration. Nat Neurosci 2004; 7: 261–8.

Staeri RL, Kim SU. Protein kinase C and mitogen-activated protein kinase signalling in oligodendrocytes. Microsc Res Tech 2001; 52: 680–8.

Stidworthy MF, Genoud S, Li WW, Leone DP, Mantei N, Suter U, et al. Notch1 and Jagged1 are expressed after CNS demyelination, but are not a major rate-determining factor during remyelination. Brain 2004; 127: 1928–41.

Syed YA, Baer AS, Lubec G, Hoeger H, Widhalm G, Kotter MR. Inhibition of oligodendrocyte precursor cell differentiation by myelin-associated proteins. Neurosurg Focus 2008; 24: E5.

Taylor CM, Pfeiffer SE. Enhanced resolution of glycosylphosphatidylinositol-anchored and transmembrane proteins from the lipid-rich myelin membrane by two-dimensional gel electrophoresis. Proteomics 2003; 3: 1303–12.

Taylor CM, Marta CB, Claycomb RJ, Han DK, Rasband MN, Coetzee T, et al. Proteomic mapping provides powerful insights into functional myelin biology. Proc Natl Acad Sci USA 2004; 101: 4643–8.

Thelen M, Rosen A, Nairn AC, Aderem A. Regulation by phosphorylation of reversible association of a myristoylated protein kinase C substrate with the plasma membrane. Nature 1991; 351: 320–2.

Thurnherr T, Benninger Y, Wu X, Chrostek A, Krause SM, Nave KA, et al. Cdc42 and Rac1 signaling are both required for and act synergistically in the correct formation of myelin sheaths in the CNS. J Neurosci 2006; 26: 10110–9.

Totoiu MO, Keirstead HS. Spinal cord injury is accompanied by chronic progressive demyelination. J Comp Neurol 2005; 486: 373–83.

Umehont H, Satot S, Yagi T, Aizawal S, Yamamoto T. Initial events of myelination involve Fyn tyrosine kinase signalling. Nature 1994; 376: 572–6.

Vanrobaey F, VanCoster R, Dhondt G, Devreeze B, VanBeeumen J. Profiling of myelin proteins by 2D-gel electrophoresis and multidimensional liquid chromatography coupled to MALDI TOF-TOF mass spectrometry. J Proteome Res 2005; 4: 2283–93.

Vicari RM, Chaitman B, Keefe D, Smith WB, Chrysant SG, Tonkon MJ, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005; 46: 1803–11.

Wang CM, Chang YY, Sun SH. Activation of P2X7 purinoceptor-stimulated TGFBeta-1 mRNA expression involves PKC/ MAPK signalling pathway in a rat brain-derived type-2 astrocyte cell line, RBA-2. Cell Signal 2003; 15: 1129–37.

Wang JK, Walaas SI, Shiha TS, Aderem A, Greengard P. Phosphorylation and associated translocation of the 87-kDa protein, a major protein kinase C substrate, in isolated nerve terminals. Proc Natl Acad Sci USA 1989; 86: 2253–6.

Weiss S, Dunne C, Hewson J, Wohl C, Wheatley M, Peterson AC, et al. Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. J Neurosci 1996; 16: 7599–609.

Werner HB, Kuhlmann K, Shen S, Uecker M, Schardt A, Dimova K, et al. Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J Neurosci 2007; 27: 7717–30.

Wittig I, Braun HP, Schagger H. Blue native PAGE. Nat Protoc 2006; 1: 418–28.

Wolf RM, Wilkes JJ, Chao MV, Resh MD. Tyrosine phosphorylation of p190 RhoGAP by Fyn regulates oligodendrocyte differentiation. J Neurobiol 2001; 49: 62–78.

Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 1998; 18: 601–9.

Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain 2002; 125: 338–49.

Wolswijk G, Noble M. Identification of an adult-specific glial progenitor cell. Development 1989; 105: 387–400.

Woodruff RA, Fruttiger M, Richardson WD, Franklin RJM. Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol Cell Neurosci 2004; 25: 252–62.

Yong VW, Cheung JC, Uhm JH, Kim SU. Age-dependent decrease of process formation by cultured oligodendrocytes is augmented by protein kinase C stimulation. J Neurosci Res 1991; 29: 87–99.

Zarate CA Jr, Singh JB, Carlson PJ, Quiroz J, Jolivette L, Luckenbaugh DA, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007; 9: 561–70.